MSU Drug Discovery Seminar - Peter Tessier, PhD
Toward drug-like antibodies by design
The biotech industry has seen an explosion in the development of therapeutic antibodies in the last decade, and today most of the best-selling drugs are monoclonal antibodies. The advantages of antibodies as therapeutics – namely their high affinity, specificity, potency, stability, manufacturability and low toxicity – are compelling. Nevertheless, there are many fundamental challenges associated with antibody discovery and development that require key technical advances in order to improve the rational generation of potent antibody therapeutics. I will discuss our progress in addressing some of these challenges, including the design, evolution, selection and characterization of drug-like antibodies with co-optimal levels of high affinity, specificity, stability and solubility.
Date: October 4, 2022
Time: 12:00 PM